These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 37864443)

  • 81. Measurable residual disease in adult acute myeloid leukaemia: evaluation of a multidimensional 'radar' flow cytometric plot analysis method.
    van der Linde R; Smith S; Brown DA; Sasson SC; Tegg E
    Pathology; 2023 Apr; 55(3):383-390. PubMed ID: 36725446
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Prognostic value of high-sensitivity measurable residual disease assessment after front-line chemoimmunotherapy in chronic lymphocytic leukemia.
    Letestu R; Dahmani A; Boubaya M; Baseggio L; Campos L; Chatelain B; Debliquis A; Drénou B; Jacob MC; Legac E; Le Garff-Tavernier M; Lhoumeau AC; Quiney C; Robillard N; Ticchioni M; Aanei C; Katsahian S; Delepine R; Vaudaux S; Rouillé V; Béné MC; Dartigeas C; Van Den Neste E; Leprêtre S; Feugier P; Cartron G; Leblond V; Lévy V; Cymbalista F;
    Leukemia; 2021 Jun; 35(6):1597-1609. PubMed ID: 32934355
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Minimal Residual Disease Quantification in Chronic Lymphocytic Leukemia: Clinical Significance and Flow Cytometric Methods.
    Böttcher S
    Methods Mol Biol; 2019; 1881():211-238. PubMed ID: 30350209
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Allogeneic stem cell transplantation for chronic lymphocytic leukemia: lessons to be learned from minimal residual disease studies.
    Böttcher S; Ritgen M; Dreger P
    Blood Rev; 2011 Mar; 25(2):91-6. PubMed ID: 21269744
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Association of Minimal Residual Disease by a Single-Tube 8-Color Flow Cytometric Analysis With Clinical Outcome in Adult B-Cell Acute Lymphoblastic Leukemia: A Real-World Study Based on 486 Patients.
    Liao H; Jiang N; Yang Y; Zhang X; Chen J; Lai H; Zheng Q
    Arch Pathol Lab Med; 2023 Oct; 147(10):1186-1195. PubMed ID: 36508349
    [TBL] [Abstract][Full Text] [Related]  

  • 86. [The detection of minimal residual disease in patients with chronic B-cell lymphatic leukemia using patient-specified polymerase chain reaction].
    Sidorova IuV; Sorokina TV; Biderman BV; Nikulina EE; Kisilichina DG; Naumova EV; Pochtar' ME; Lugovskaia SA; Ivanova VL; Kovaleva LG; Ptushkin VV; Nikitin EA; Sudarikov AB
    Klin Lab Diagn; 2011 Dec; (12):22-4, 33-5. PubMed ID: 22416427
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Minimal/Measurable Residual Disease Detection in Acute Leukemias by Multiparameter Flow Cytometry.
    Fuda F; Chen W
    Curr Hematol Malig Rep; 2018 Dec; 13(6):455-466. PubMed ID: 30446941
    [TBL] [Abstract][Full Text] [Related]  

  • 88. [The clinical significance of detecting minimal residual disease in acute childhood B-cell lymphoblastic leukemia with flow cytometry].
    Zhang LP; Cheng YF; Liu GL; Lu AD; Liu YR; Wang H
    Zhonghua Er Ke Za Zhi; 2005 Jul; 43(7):481-5. PubMed ID: 16083543
    [TBL] [Abstract][Full Text] [Related]  

  • 89. [Expression of CD123 in lymphocytic leukemia and its significance for monitoring minimal residual diseases.].
    Wang YF; Chen BG; Luo WD; Zheng R; Li BL
    Zhonghua Xue Ye Xue Za Zhi; 2010 Apr; 31(4):244-8. PubMed ID: 20510041
    [TBL] [Abstract][Full Text] [Related]  

  • 90. [Minimal residual disease in chronic lymphocytic leukemia: A still current issue in 2018].
    Gauthier M; Comont T; Vergez F; Ysebaert L
    Bull Cancer; 2018 Nov; 105(11):1042-1051. PubMed ID: 30243477
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Minimal Residual Disease and Survival Outcomes in Patients With Chronic Lymphocytic Leukemia: A Systematic Review and Meta-analysis.
    Molica S; Giannarelli D; Montserrat E
    Clin Lymphoma Myeloma Leuk; 2019 Jul; 19(7):423-430. PubMed ID: 31027992
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Evaluation of multiple myeloma measurable residual disease by high sensitivity flow cytometry: An international harmonized approach for data analysis.
    Soh KT; Came N; Otteson GE; Jevremovic D; Shi M; Olteanu H; Natoni A; Lagoo A; Theakston E; Óskarsson JÞ; Gorniak M; Grigoriadis G; Arroz M; Fletcher M; Lin P; Ludwig P; Tembhare P; Matuzeviciene R; Radzevicius M; Kay S; Chen W; Cabrita C; Wallace PK
    Cytometry B Clin Cytom; 2022 Mar; 102(2):88-106. PubMed ID: 35005838
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendations.
    Wierda WG; Rawstron A; Cymbalista F; Badoux X; Rossi D; Brown JR; Egle A; Abello V; Cervera Ceballos E; Herishanu Y; Mulligan SP; Niemann CU; Diong CP; Soysal T; Suzuki R; Tran HTT; Wu SJ; Owen C; Stilgenbauer S; Ghia P; Hillmen P
    Leukemia; 2021 Nov; 35(11):3059-3072. PubMed ID: 34168283
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Time point-dependent concordance and prognostic significance of flow cytometry and real time quantitative PCR for measurable/minimal residual disease detection in acute myeloid leukemia with t(8;21)(q22;q22.1).
    Shang L; Cai X; Sun W; Cheng Q; Mi Y
    Cytometry B Clin Cytom; 2022 Jan; 102(1):34-43. PubMed ID: 34232569
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Comparative analysis of different approaches to measure treatment response in acute myeloid leukemia.
    Inaba H; Coustan-Smith E; Cao X; Pounds SB; Shurtleff SA; Wang KY; Raimondi SC; Onciu M; Jacobsen J; Ribeiro RC; Dahl GV; Bowman WP; Taub JW; Degar B; Leung W; Downing JR; Pui CH; Rubnitz JE; Campana D
    J Clin Oncol; 2012 Oct; 30(29):3625-32. PubMed ID: 22965955
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Immunophenotypic measurable residual disease (MRD) in acute myeloid leukemia: Is multicentric MRD assessment feasible?
    Brooimans RA; van der Velden VHJ; Boeckx N; Slomp J; Preijers F; Te Marvelde JG; Van NM; Heijs A; Huys E; van der Holt B; de Greef GE; Kelder A; Schuurhuis GJ
    Leuk Res; 2019 Jan; 76():39-47. PubMed ID: 30553189
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Analysis of residual disease in chronic lymphocytic leukemia by flow cytometry.
    Cabezudo E; Matutes E; Ramrattan M; Morilla R; Catovsky D
    Leukemia; 1997 Nov; 11(11):1909-14. PubMed ID: 9369425
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Quantitative flow cytometry of ZAP-70 levels in chronic lymphocytic leukemia using molecules of equivalent soluble fluorochrome.
    Kay S; Herishanu Y; Pick M; Rogowski O; Baron S; Naparstek E; Polliack A; Deutsch VR
    Cytometry B Clin Cytom; 2006 Jul; 70(4):218-26. PubMed ID: 16456869
    [TBL] [Abstract][Full Text] [Related]  

  • 99. How I Diagnose Minimal/Measurable Residual Disease in B Lymphoblastic Leukemia/Lymphoma by Flow Cytometry.
    Cherian S; Soma LA
    Am J Clin Pathol; 2021 Jan; 155(1):38-54. PubMed ID: 33236071
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Quantitative molecular monitoring of residual tumor cells in chronic lymphocytic leukemia.
    Pfitzner T; Reiser M; Barth S; Borchmann P; Schulz H; Schinköthe T; Oberhäuser F; Wessels J; Tur M; Diehl V; Engert A
    Ann Hematol; 2002 May; 81(5):258-66. PubMed ID: 12029535
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.